A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

BACKGROUND: In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established for acute myeloid leukemia (AML), the most common form of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Naveen K, Pfluegler, Martin, Meetze, Kristan, Li, Bochong, Sindel, Isabelle, Vogt, Fabian, Marklin, Melanie, Heitmann, Jonas S, Kauer, Joseph, Osburg, Lukas, Zekri, Latifa, Bühring, Hans-Jörg, Mueller, Stefanie, Hörner, Sebastian, Baeuerle, Patrick A, Michaelson, Jennifer S, Jung, Gundram, Salih, Helmut R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921914/
https://www.ncbi.nlm.nih.gov/pubmed/35288466
http://dx.doi.org/10.1136/jitc-2021-003882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921914/
https://www.ncbi.nlm.nih.gov/pubmed/35288466
http://dx.doi.org/10.1136/jitc-2021-003882

Ejemplares similares